Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design

Hengmiao Cheng(Pfizer (United States)), Eric Zhang, Sacha Ninkovic(Pfizer (United States)), Shubha Bagrodia(Scripps Research Institute), Robert S. Kania(RG Biopharma (United States)), Martin P. Edwards(Pfizer (United States)), Shaoxian Sun, Simon Bailey(The University of Melbourne), Daniel R. Knighton(Pfizer (United States)), Matthew A. Marx(Mirati Therapeutics (United States)), Jacqui Hoffman(Pfizer (United States)), Qiyue Hu

MedChemComm

January 1, 2010

10.1039/c0md00072h

Cited by 73

Related Papers

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

|Journal of Medicinal Chemistry|2011|924

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

|Acta Neuropathologica|2016|650

Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations

|Journal of Medicinal Chemistry|2014|587

Using the Golden Triangle to optimize clearance and oral absorption

|Bioorganic & Medicinal Chemistry Letters|2009|382

Lipophilic Efficiency as an Important Metric in Drug Design

|Journal of Medicinal Chemistry|2018|340